Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
glaucoma management across 13 countries in central eastern and southeastern europe an exploratory survey
Original title: “Glaucoma management across 13 countries in Central, Eastern and Southeastern Europe: an exploratory survey.”
novel dual device strategy failed preserflo microshunt connected to an ahmed clearpath case report
Original title: “Novel Dual-Device Strategy: Failed PRESERFLO MicroShunt Connected to an Ahmed ClearPath - Case Report.”
delayed onset giant bleb formation and persistent intraocular pressure elevation in a patient with covid 19 and a long term ahmed glaucoma valve
Original title: “Delayed-Onset Giant Bleb Formation and Persistent Intraocular Pressure Elevation in a Patient With COVID-19 and a Long-Term Ahmed Glaucoma Valve.”
4 phenylbutyric acid loaded mesoporous silica nanoparticles alleviate endoplasmic reticulum stress and reduce intraocular pressure in glaucoma model
Original title: “4-phenylbutyric acid-loaded mesoporous silica nanoparticles alleviate endoplasmic reticulum stress and reduce intraocular pressure in glaucoma model.”
According to a news release, Oculis officials hope to forward product candidates to address areas of significant medical needs, including diabetic macular edema, dry eye disease, and neuro-retina indications such as glaucoma, affecting growing patient populations. According to a news release, Oculis officials hope to forward product candidates to address areas of significant medical needs, including diabetic macular edema, dry eye disease, and neuro-retina indications such as glaucoma, affecting growing patient populations. ... Oculis, SA and European Biotech Acquisition Corp. OCS-05 is a serum-glucocorticoid kinase 2 (SGK-2) activator, in development as a potential disease-modifying neuroprotective agent to address neurological damage to the optic nerve. OCS-05 is initially in development as a potential therapeutic for acute optic neuritis, or AON, a rare disease with high unmet need as currently, there is no approved treatment for AON. “EBAC was formed to invest in the untapped potential in the European biotechnology sector and has screened over 100 European biotechnology companies,” he said in the news release. “Oculis is a prime example of what we set out to invest in, with great innovation, a well thought out strategy and an experienced management team to bring promising therapies to market for patients suffering from eye disease.” OCS-01 was purposefully designed to enable a potential breakthrough approach in the treatment of retinal diseases; a topical, non-invasive approach. Current therapies require intra-ocular injections. Effective topical therapies would complement the existing approaches by adding an option with improved patient comfort, safety, accessibility, cost and allowing individualized dosing.
Original title: “Oculis SA, European Biotech Acquisition Corp. announce business combination agreement | Ophthalmology Times - Clinical Insights for Eye Specialists”
ocular manifestations of a rare congenital heart defect advanced glaucoma and retinal vein occlusion associated with double chambered right ventricle
Original title: “Ocular manifestations of a rare congenital heart defect: Advanced glaucoma and retinal vein occlusion associated with double-chambered right ventricle.”
Stem cell technologies company Axol Bioscience has acquired the ophthalmology business of Newcells Biotech. The acquisition of Newcells’ ophthalmology business includes its specialist team, facilities and intellectual property related to supply of proprietary iPSC-derived products and ophthalmology research services to biopharma, biotechnology and CRO customers across Europe and the US. The platforms encompass advanced retinal organoids and 2D retinal pigment epithelium (RPE) models designed to support preclinical research and translational drug development. Growing investment in research to discover new therapeutics for eye diseases such as age-related macular degeneration, glaucoma and rare disease has driven Axol’s strategic expansion into ophthalmology, with Phenocell previously acquiredin October 2024.
Original title: “Axol to progress eye disease treatments with new acquisition - Drug Discovery World (DDW)”